Theranos Economic Model Clashed With Clinical Lab Standards on Sample Volume and Physician Oversight
The Theranos model was incompatible with routine lab operations requiring excess sample for repeats and physician authorization for reimbursement. Letters in STAT underscore these non-technical barriers. Regulatory and economic integration remains essential for any blood-testing innovation.
Related analyses in Clinical Chemistry (2018) and a 2022 NEJM Perspective on lab stewardship reinforce that volume and ordering constraints protect diagnostic accuracy and billing integrity. Future direct-access models will need explicit integration with these workflows or risk repeating Theranos' operational collapse even with accurate assays.
CLIA: At least two new direct-to-consumer blood testing firms will file CLIA waivers with explicit excess-sample retention protocols by Q4 2027 or face state-level reimbursement blocks.
Sources (3)
- [1]Primary Source(https://www.statnews.com/2026/10/24/you-can-see-everything-stat-letters-to-editor/)
- [2]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMp2204223)
- [3]Supporting Source(https://academic.oup.com/clinchem/article/64/1/1/5607993)